1. Home
  2. SD vs ARVN Comparison

SD vs ARVN Comparison

Compare SD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SandRidge Energy Inc.

SD

SandRidge Energy Inc.

N/A

Current Price

$14.33

Market Cap

502.8M

Sector

Energy

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$8.98

Market Cap

516.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SD
ARVN
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
502.8M
516.2M
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
SD
ARVN
Price
$14.33
$8.98
Analyst Decision
Strong Sell
Buy
Analyst Count
1
19
Target Price
$15.00
$15.05
AVG Volume (30 Days)
280.8K
858.7K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
3.07%
N/A
EPS Growth
12.43
58.84
EPS
1.22
1.70
Revenue
N/A
$262,600,000.00
Revenue This Year
$12.65
N/A
Revenue Next Year
$1.75
N/A
P/E Ratio
$11.61
$5.69
Revenue Growth
N/A
N/A
52 Week Low
$11.10
$6.97
52 Week High
$18.45
$14.22

Technical Indicators

Market Signals
Indicator
SD
ARVN
Relative Strength Index (RSI) 56.69 54.71
Support Level $13.85 $7.90
Resistance Level $14.34 $9.65
Average True Range (ATR) 0.37 0.42
MACD 0.07 0.06
Stochastic Oscillator 80.25 60.45

Price Performance

Historical Comparison
SD
ARVN

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: